{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T01:05:32Z","timestamp":1776215132831,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#2015\/03756\u20134"],"award-info":[{"award-number":["#2015\/03756\u20134"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#2019\/17272\u20130"],"award-info":[{"award-number":["#2019\/17272\u20130"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#2019\/21211\u20136"],"award-info":[{"award-number":["#2019\/21211\u20136"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#2019\/11776-6"],"award-info":[{"award-number":["#2019\/11776-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["CNPq #305242\/2019\u20139"],"award-info":[{"award-number":["CNPq #305242\/2019\u20139"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["#304984\/2020\u20135"],"award-info":[{"award-number":["#304984\/2020\u20135"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["#303379\/2018\u20139"],"award-info":[{"award-number":["#303379\/2018\u20139"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"B3 - Bolsa de Valores do Brasil"},{"name":"Faculdade de Medicina da USP\u2014SP"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies (SAMs) and the possible influence of baseline disease parameters, comorbidities and therapy on immune response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective controlled study included 53 patients with SAMs and 106 non-immunocompromised control group (CTRL). All participants received two doses of the Sinovac-CoronaVac vaccine (28-day interval). Immunogenicity was assessed by anti-SARS-CoV-2 S1\/S2 IgG seroconversion (SC), anti-S1\/S2 IgG geometric mean titre (GMT), factor increase GMT (FI-GMT), neutralizing antibodies (NAb) positivity, and median neutralizing activity after each vaccine dose (D0 and D28) and six weeks after the second dose (D69). Participants with pre-vaccination positive IgG serology and\/or NAb and those with RT-PCR confirmed COVID-19 during the protocol were excluded from immunogenicity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients and CTRL had comparable sex (P&amp;gt;0.99) and age (P=0.90). Immunogenicity of 37 patients and 79 CTRL-na\u00efve participants revealed at D69, a moderate but significantly lower SC (64.9% vs 91.1%, P&amp;lt;0.001), GMT [7.9 (95%CI 4.7\u201313.2) vs 24.7 (95%CI 30.0\u201330.5) UA\/ml, P&amp;lt;0.001] and frequency of NAb (51.4% vs 77.2%, P&amp;lt;0.001) in SAMs compared with CTRL. Median neutralizing activity was comparable in both groups [57.2% (interquartile range (IQR) 43.4\u201383.4) vs 63.0% (IQR 40.3\u201380.7), P=0.808]. Immunosuppressives were less frequently used among NAb+ patients vs NAb- patients (73.7% vs 100%, P=0.046). Type of SAMs, disease status, other drugs or comorbidities did not influence immunogenicity. Vaccine-related adverse events were mild with similar frequencies in patients and CTRL (P&amp;gt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sinovac-CoronaVac is safe and has a moderate short-term immunogenicity in SAMs, but reduced compared with CTRL. We further identified that immunosuppression is associated with diminished NAb positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV\/AIDS (CoronavRheum), http:\/\/clinicaltrials.gov\/ct2\/show\/NCT04754698<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab773","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T16:34:12Z","timestamp":1634142852000},"page":"3351-3361","source":"Crossref","is-referenced-by-count":17,"title":["Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2"],"prefix":"10.1093","volume":"61","author":[{"given":"Samuel K","family":"Shinjo","sequence":"first","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando H C","family":"de Souza","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela B P","family":"Borges","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre M","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Miossi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael G","family":"Misse","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C","family":"Medeiros-Ribeiro","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla G S","family":"Saad","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily F N","family":"Yuki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra G","family":"Pasoto","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onard V K","family":"Kupa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Ceneviva","sequence":"additional","affiliation":[{"name":"Central Laboratory Division"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia C","family":"Seraphim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana N","family":"Pedrosa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarete B G","family":"Vendramini","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00f3vis A","family":"Silva","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, Childrens\u2019 Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo , SP,","place":["Brazil (BR)"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00e1dia E","family":"Aikawa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"},{"name":"Pediatric Rheumatology Unit, Childrens\u2019 Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo , SP,","place":["Brazil (BR)"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4681","authenticated-orcid":false,"given":"Eloisa","family":"Bonf\u00e1","sequence":"additional","affiliation":[{"name":"Division of Rheumatology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"2026041420130366900_keab773-B1","year":"2021"},{"key":"2026041420130366900_keab773-B2","doi-asserted-by":"crossref","first-page":"e05684","DOI":"10.1016\/j.heliyon.2020.e05684","article-title":"Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: meta-analysis with 55 studies and 10014 cases","volume":"6","author":"Barek","year":"2020","journal-title":"Heliyon"},{"key":"2026041420130366900_keab773-B3","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1038\/s41598-021-88130-w","article-title":"A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19","volume":"11","author":"Thakur","year":"2021","journal-title":"Sci Rep"},{"key":"2026041420130366900_keab773-B4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1111\/dom.14124","article-title":"Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis","volume":"22","author":"Singh","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026041420130366900_keab773-B5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/annrheumdis-2021-219845","article-title":"Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study","volume":"80","author":"Bower","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1506827","article-title":"Inflammatory muscle diseases","volume":"373","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"2026041420130366900_keab773-B8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026041420130366900_keab773-B9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2026041420130366900_keab773-B10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/keaa610","article-title":"COVID-19 and myositis - unique challenges for patients","volume":"60","author":"Gupta","year":"2021","journal-title":"Rheumatology"},{"key":"2026041420130366900_keab773-B11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","article-title":"Infectious complications in polymyositis and dermatomyositis: a series of 279 patients","volume":"41","author":"Marie","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2026041420130366900_keab773-B12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s42358-019-0048-x","article-title":"Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies","volume":"59","author":"De Souza","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2026041420130366900_keab773-B13","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B14","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00296-021-04917-0","article-title":"Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey","volume":"41","author":"Cherian","year":"2021","journal-title":"Rheumatol Int"},{"key":"2026041420130366900_keab773-B17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Boyarsky","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B18","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B20","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"2026041420130366900_keab773-B21","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s10067-020-05013-7","article-title":"A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome","volume":"39","author":"Behrens Pinto","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026041420130366900_keab773-B22","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile myositis","volume":"30","author":"Rider","year":"2003","journal-title":"J Rheumatol"},{"key":"2026041420130366900_keab773-B23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/rheumatology\/ken441","article-title":"Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis","volume":"48","author":"Harris-Love","year":"2009","journal-title":"Rheumatology"},{"key":"2026041420130366900_keab773-B24","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology"},{"key":"2026041420130366900_keab773-B25","doi-asserted-by":"crossref","first-page":"e02438","DOI":"10.1128\/JCM.02438-20","article-title":"A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection","volume":"59","author":"Taylor","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2026041420130366900_keab773-B26","doi-asserted-by":"crossref","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill"},{"key":"2026041420130366900_keab773-B27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","article-title":"Considering how biological sex impacts immune responses and COVID-19 outcomes","volume":"20","author":"Scully","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2026041420130366900_keab773-B28","doi-asserted-by":"crossref","first-page":"601170","DOI":"10.3389\/fimmu.2020.601170","article-title":"Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens","volume":"11","author":"Fathi","year":"2020","journal-title":"Front Immunol"},{"key":"2026041420130366900_keab773-B29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2012.10.063","article-title":"Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease","volume":"31","author":"Shinjo","year":"2012","journal-title":"Vaccine"},{"key":"2026041420130366900_keab773-B30","year":"2018"},{"key":"2026041420130366900_keab773-B31"},{"key":"2026041420130366900_keab773-B32"},{"key":"2026041420130366900_keab773-B33","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2011.150250","article-title":"Immunogenicity and safety of the 2009 non-adjuvanted influenza A\/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases","volume":"70","author":"Saad","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026041420130366900_keab773-B34","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"2026041420130366900_keab773-B35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.41734","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026041420130366900_keab773-B36","doi-asserted-by":"crossref","first-page":"102649","DOI":"10.1016\/j.jaut.2021.102649","article-title":"A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine","volume":"121","author":"Moutsopoulos","year":"2021","journal-title":"J Autoimmun"},{"key":"2026041420130366900_keab773-B37","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1093\/rheumatology\/keab223","article-title":"COVID-19 vaccination and antirheumatic therapy","volume":"60","author":"Arnold","year":"2021","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab773\/41023431\/keab773.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/8\/3351\/45226650\/keab773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/8\/3351\/45226650\/keab773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:22:03Z","timestamp":1776212523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/8\/3351\/6402018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab773","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2021,10,19]]}}}